Key facts
- Luwei’s last known valuation is $23.7M (Dec 2023).
- It has raised $1.4M; the latest was Early Stage VC in Jan 2026.
- Notable investors include Jiangxi Gantou Investment, Changye Investment Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Luwei
- ·The full record, as it builds
Funding rounds
No funding rounds for Luwei are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Luwei
Operator of diagnostic technologies intended to transform disease detection and clinical decision-making. The company offers molecular probes, transcriptomic algorithms, and immunoassay technologies, enabling physicians, patients, and pharmaceutical enterprises to achieve precise diagnostics, early intervention, and personalized treatment outcomes.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2021
- Website
- biomanifold.com/
- Ownership
- Privately Held (backing)
Luwei doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Luwei shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Luwei in its N-PORT filings yet. We sweep new filings monthly.